Article thumbnail

Leishmania donovani Isolates with Antimony-Resistant but Not -Sensitive Phenotype Inhibit Sodium Antimony Gluconate-Induced Dendritic Cell Activation

By Arun Kumar Haldar, Vinod Yadav, Eshu Singhal, Kamlesh Kumar Bisht, Alpana Singh, Suniti Bhaumik, Rajatava Basu, Pradip Sen and Syamal Roy

Abstract

The inability of sodium antimony gluconate (SAG)-unresponsive kala-azar patients to clear Leishmania donovani (LD) infection despite SAG therapy is partly due to an ill-defined immune-dysfunction. Since dendritic cells (DCs) typically initiate anti-leishmanial immunity, a role for DCs in aberrant LD clearance was investigated. Accordingly, regulation of SAG-induced activation of murine DCs following infection with LD isolates exhibiting two distinct phenotypes such as antimony-resistant (SbRLD) and antimony-sensitive (SbSLD) was compared in vitro. Unlike SbSLD, infection of DCs with SbRLD induced more IL-10 production and inhibited SAG-induced secretion of proinflammatory cytokines, up-regulation of co-stimulatory molecules and leishmanicidal effects. SbRLD inhibited these effects of SAG by blocking activation of PI3K/AKT and NF-κB pathways. In contrast, SbSLD failed to block activation of SAG (20 µg/ml)-induced PI3K/AKT pathway; which continued to stimulate NF-κB signaling, induce leishmanicidal effects and promote DC activation. Notably, prolonged incubation of DCs with SbSLD also inhibited SAG (20 µg/ml)-induced activation of PI3K/AKT and NF-κB pathways and leishmanicidal effects, which was restored by increasing the dose of SAG to 40 µg/ml. In contrast, SbRLD inhibited these SAG-induced events regardless of duration of DC exposure to SbRLD or dose of SAG. Interestingly, the inhibitory effects of isogenic SbSLD expressing ATP-binding cassette (ABC) transporter MRPA on SAG-induced leishmanicidal effects mimicked that of SbRLD to some extent, although antimony resistance in clinical LD isolates is known to be multifactorial. Furthermore, NF-κB was found to transcriptionally regulate expression of murine γglutamylcysteine synthetase heavy-chain (mγGCShc) gene, presumably an important regulator of antimony resistance. Importantly, SbRLD but not SbSLD blocked SAG-induced mγGCS expression in DCs by preventing NF-κB binding to the mγGCShc promoter. Our findings demonstrate that SbRLD but not SbSLD prevents SAG-induced DC activation by suppressing a PI3K-dependent NF-κB pathway and provide the evidence for differential host-pathogen interaction mediated by SbRLD and SbSLD

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2873921
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1981). A quick, simple method for purifying Leishmania mexicana amastigotes in large numbers.
  2. (2008). Abnormal NF-kappaB function characterizes human type 1 diabetes dendritic cells and monocytes.
  3. (2000). Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB.
  4. (1994). Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani.
  5. (2007). Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells.
  6. (2008). Critical role of dendritic cells in determining the Th1/Th2 balance upon Leishmania major infection.
  7. (2009). Cutaneous leishmaniasis: disease susceptibility and pharmacogenetic implications.
  8. (2005). DCSIGN-mediated transfer of HIV-1 is compromised by the ability of Leishmania infantum to exploit DC-SIGN as a ligand.
  9. (2002). Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis.
  10. (2002). Dendritic cell development and survival require distinct NF-kappaB subunits.
  11. (1998). Dendritic cell survival and maturation are regulated by different signaling pathways.
  12. (2001). Dendritic cells from nonobese diabetic mice exhibit a defect in NFkappaB regulation due to a hyperactive IkappaB kinase.
  13. (1998). Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection.
  14. (2005). Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappaB inhibitory proteins IkappaB alpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells.
  15. (2007). Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray.
  16. (1997). Differential regulation of gammaglutamylcysteine synthetase heavy and light subunit gene expression.
  17. (2006). Drug resistance in leishmaniasis.
  18. (2009). Dube A
  19. (2000). Dynamics of NF-kappaB and IkappaB alpha studied with green fluorescent protein (GFP) fusion proteins. Investigation of GFP-p65 binding to DNA by fluorescence resonance energy transfer.
  20. (2002). Elevated NFkappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function.
  21. (1999). Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
  22. (2005). Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.
  23. (2007). HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis.
  24. (2006). Hoffmann A
  25. (1999). How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex.
  26. (2001). IL-10 mediates susceptibility to Leishmania donovani infection.
  27. (2000). IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/ CD40 ligand-dependent process.
  28. (2004). Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity.
  29. (2005). Increase of intracellular glutathione by low-level NO mediated by transcription factor NF-kappaB in RAW 264.7 cells.
  30. (2003). Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR ‘‘homotolerance’’ versus ‘‘heterotolerance’’ on NF-kappaB signaling pathway components.
  31. (2007). Inhibition of groups 1 and 2 CD1 molecules on human dendritic cells by Leishmania species.
  32. (2002). Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
  33. (2000). Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
  34. (1997). Israel A
  35. (2001). Leishmania amazonensis-dendritic cell interactions in vitro and the priming of parasite-specific CD4(+) T cells in vivo.
  36. (2005). Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts.
  37. (2009). Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
  38. (2009). Leishmania infantum Amastigotes Enhance
  39. (2002). Missing pieces in the NF-kappaB puzzle.
  40. (2007). Molecular mechanisms of antimony resistance in Leishmania.
  41. (2003). Novel mechanism of drug resistance in kala azar field isolates.
  42. (1988). Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
  43. (2007). Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
  44. (2007). Proteophosphoglycan is differentially expressed in sodium stibogluconatesensitive and resistant Indian clinical isolates of Leishmania donovani.
  45. (2005). Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
  46. (1995). Regulation of interleukin 12 p40 expression through an NF-kappaB half-site.
  47. (2006). Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein.
  48. (2001). Regulatory activity of autocrine IL-10 on dendritic cell functions.
  49. (2006). Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.
  50. (2007). Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy.
  51. (2007). Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani.
  52. (2000). Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
  53. (1999). SHP-1 regulates Lckinduced phosphatidylinositol 3-kinase phosphorylation and activity.
  54. (2001). Silent infection of bone marrow-derived dendritic cells by Leishmania mexicana amastigotes.
  55. (2008). Sinha A
  56. (2003). Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate.
  57. (2006). Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.
  58. (2001). Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
  59. (2003). The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
  60. (2002). The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells.
  61. (2006). Toll-like receptor-positive cells and recognition of pathogens: how human myeloid dendritic cells respond to in vitro infection with Leishmania infantum.
  62. (1993). Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkappaB alpha: a mechanism for NF-kappaB activation.
  63. (2006). Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
  64. (2008). Wild-type Leishmania donovani promastigotes block maturation, increase integrin expression and inhibit detachment of human monocyte-derived dendritic cells–the influence of phosphoglycans.